2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Eukaryotic Initiation Factor (eIF)
  5. Eukaryotic Initiation Factor (eIF) Inhibitor

Eukaryotic Initiation Factor (eIF) Inhibitor

Eukaryotic Initiation Factor (eIF) Inhibitors (50):

Cat. No. Product Name Effect Purity
  • HY-112654
    GCN2iB
    		Inhibitor 99.83%
    GCN2iB is an ATP-competitive inhibitor of a serine/threonine-protein kinase general control nonderepressible 2 (GCN2), with an IC50 of 2.4 nM.
  • HY-100877
    GCN2-IN-1
    		Inhibitor ≥98.0%
    GCN2-IN-1 (A-92) is a potent general control nonderepressible 2 kinase (GCN2) inhibitor with an IC50 of <0.3 μM in the enzyme assay and an IC50 of 0.3-3 μM in the cell assay.
  • HY-19356
    Rocaglamide
    		Inhibitor 99.34%
    Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC50 of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia.
  • HY-112163
    Zotatifin
    		Inhibitor 99.69%
    Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC50=2 nM) and interferes with the assembly of the eIF4F initiation complex. Zotatifin shows robust antiviral effects, it effectively reduces viral infectivity by inhibiting SARS-CoV-2 NP protein biogenesis (IC90=37 nM). Zotatifin induces cell apoptosis.
  • HY-148664
    eIF4E-IN-4
    		Inhibitor
    eIF4E-IN-4 (Compound 33) is a selective inhibitor of eukaryotic initiation factor 4E (eIF4E) with biochemical activity value of 95 nM. eIF4E-IN-4 inhibits cap-dependent mRNA translation with an IC50 value of 2.5 μM. eIF4E-IN-4 can be used for breast cancer, colon cancer, and head and neck cancer study.
  • HY-19831
    4EGI-1
    		Inhibitor 98.32%
    4EGI-1 is an inhibitor of eIF4E/eIF4G interaction, with a Kd of 25 μM against eIF4E binding.
  • HY-13251
    Silvestrol
    		Inhibitor 99.96%
    Silvestrol is a eukaryotic translation initiation factor 4A (eIF4A) inhibitor isolated from Agave americana Linn.. Silvestrol induces autophagy and caspase-mediated apoptosis.
  • HY-136453
    CR-1-31-B
    		Inhibitor 98.38%
    CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells.
  • HY-14427
    4E1RCat
    		Inhibitor 98.99%
    4E1RCat is an inhibitor of cap-dependent translation, and inhibits eIF4E:eIF4GI interaction, with an IC50 an of ～4 μM.
  • HY-130240
    GCN2-IN-6
    		Inhibitor 98.89%
    GCN2-IN-6 (Compound 6d) is a potent, and orally available GCN2 inhibitor confirmed by in-house enzymatic (IC50 of 1.8 nM) and cellular assays (IC50 of 9.3 nM). GCN2-IN-6 is also a eIF2α kinase PERK inhibitor with an IC50 of 0.26 nM (in enzymatic assay) and 230 nM (in cells). GCN2-IN-6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-101785
    eIF4A3-IN-2
    		Inhibitor 99.70%
    eIF4A3-IN-2 is a highly selective and noncompetitive eukaryotic initiation factor 4A-3 (eIF4A3) inhibitor with an IC50 of 110 nM.
  • HY-19560
    SBI-0640756
    		Inhibitor 99.75%
    SBI-0640756 (SBI-756) is an inhibitor of eIF4G1 and disrupts the eIF4F complex.
  • HY-101513
    eIF4A3-IN-1
    		Inhibitor 99.96%
    eIF4A3-IN-1 (compound 53a) is a selective eukaryotic initiation factor 4A3 (eIF4A3) inhibitor (IC50=0.26 μM; Kd=0.043 μM), which binds to a non-ATP binding site of eIF4A3 and shows significant cellular nonsense-mediated RNA decay (NMD) inhibition at 10 and 3 μM and can be as a probe for further study of eIF4A3, the exon junction complex (EJC), and NMD.
  • HY-151460
    GCN2-IN-7
    		Inhibitor 99.85%
    GCN2-IN-7 (compound 39) is an orally active and selective general control nonderepressible 2 (GCN2) inhibitor (IC50=5 nM). GCN2-IN-7 shows anti-tumor activity in vivo.
  • HY-N7071A
    Maduramicin ammonium
    		Inhibitor 99.89%
    Maduramicin ammonium (Maduramycin ammonium) is isolated from the actinomycete Actinomadura rubra. Maduramicin ammonium (Maduramycin ammonium) is an anticoccidial agent for the the treatment of Eimeria spp., E. adenoeides, E. gallopavonis, and E. dispersa infection. Maduramicin ammonium (Maduramycin ammonium) induces cell apoptosis in chicken myocardial cells via intrinsic and extrinsic pathways.
  • HY-16366
    Briciclib
    		Inhibitor 99.63%
    Briciclib (ON 014185) is a derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.
  • HY-100733
    4E2RCat
    		Inhibitor ≥98.0%
    4E2RCat is an inhibitor of eIF4E-eIF4G interaction with an IC50 of 13.5 μM.
  • HY-148422
    Rohinitib
    		Inhibitor 99.40%
    Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML.
  • HY-19356A
    Didesmethylrocaglamide
    		Inhibitor 98.49%
    Didesmethylrocaglamide, a derivative of Rocaglamide, is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. Didesmethylrocaglamide has potent growth-inhibitory activity with an IC50 of 5 nM. Didesmethylrocaglamide suppresses multiple growth-promoting signaling pathways and induces apoptosis in tumor cells. Antitumor activity.
  • HY-145262
    eIF4E-IN-2
    		Inhibitor 98.76%
    eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e). eIF4E-IN-2 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 1188). eIF4E-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.